Table 1 Study participants’ characteristics (n = 104)
Variables | Drug given | p-value | |
|---|---|---|---|
Generic n (%) | Innovator n (%) | Â | |
Age (months) | |||
 ≤ 24 | 25 (62.5%) | 15 (37.5%) | 0.12 |
 > 24 | 30 (46.9%) | 34 (53.1%) |  |
Sex | |||
 Female | 28 (57.1%) | 21 (42.9%) | 0.41 |
 Male | 27 (49.1%) | 28 (50.9%) |  |
Weight (kg) | |||
 < 15 | 39 (50.6%) | 38 (49.4%) | 0.44 |
 ≥ 15 | 16 (59.3%) | 11 (40.7%) |  |
Baseline temperature | |||
 < 37.5 ℃ | 9 (52.9%) | 8 (47.1%) | 0.99 |
 ≥ 37.5 ℃ | 46 (52.9%) | 41 (47.1%) |  |
Baseline hemoglobin (g/dl) | |||
 < 11 | 41 (56.9%) | 31 (43.1%) | 0.30 |
 ≥ 11 | 12 (48%) | 13 (52%) |  |
Baseline parasitaemia (/µl) | |||
 < 1000 | 15 (65.2%) | 8 (34.8%) |  |
 1000–10,000 | 7 (29.2%) | 17 (70.8%) |  |
 ≥ 10,000 | 33 (57.9%) | 24 (42.1%) | 0.025 |